Figure 1.

Treatment with Hcrt-1 produced short and longer-term changes in cataplexy. a: Intravenous injection of Hcrt-1 produced a dose dependent change in cataplexy. b: FECT time also showed a dose dependent change. Doses of 1 and 2 µg/kg did not affect cataplexy. Doses of 3 µg/kg produced a significant decrease in the number of falls (a) and in the time it took to consume the food (eating time + cataplexy time) (b). In contrast, 4 µg/kg doses significantly increased the number of falls (a) and the time required to consume the food (b) relative to baseline (dotted line). c-d: In the two dogs tested with repeated doses of Hcrt-1, a complete suppression of cataplexy resulted following the last dose. c: Three doses of Hcrt-1 produced a complete suppression of cataplexy for three consecutive days. d: In a more severely affected dog, the administration of five doses of Hcrt-1 produced a complete suppression of cataplexy during the FECT observed on three tests given over a six day period. c' and d' show the FECT time on the days of the tests in c and d respectively. Arrows indicate days in which the FECT was done with Hcrt-1 treatment, and doses are indicated in parentheses. On all the other days animals were tested after the administration of the same volume of saline. All values in a and b are mean ±SE; P=average of pretreatment days, +p<0.05, ++p<0.01, +++p<0.001 compared to saline control, t-test; *p<0.05, **p<0.01, between doses, Newman-Keuls test. ‡ indicates no cataplexy attacks observed during the FECT.